Consolidated Statement of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Cash Flows from Operating Activities
Net income	$ 17,133	$ 377	$ 14,526
Adjustments to reconcile net income to net cash provided by operating activities:
Amortization	2,395	2,044	2,085
Depreciation	2,104	1,828	1,824
Intangible asset impairment charges	39	792	1,749
(Income) loss from investments in equity securities, net	(14)	(340)	1,419
Charges for certain research and development asset acquisitions	3,456	11,409	0
Deferred income taxes	(1,249)	(1,899)	(1,568)
Share-based compensation	761	645	541
Other	510	355	1,301
Net changes in assets and liabilities:
Accounts receivable	(244)	(1,148)	(644)
Inventories	(835)	(816)	(161)
Trade accounts payable	182	(380)	(289)
Accrued and other current liabilities	(2,328)	1,783	(50)
Income taxes payable	1,023	214	380
Noncurrent liabilities	(49)	456	(545)
Other	(1,416)	(2,314)	(1,473)
Net Cash Provided by Operating Activities	21,468	13,006	19,095
Cash Flows from Investing Activities
Capital expenditures	(3,372)	(3,863)	(4,388)
Purchases of securities and other investments	(519)	(955)	(1,204)
Proceeds from sale of Seagen Inc. common stock	0	1,145	0
Proceeds from sales of securities and other investments	377	1,658	721
Acquisition of Eyebiotech Limited, net of cash acquired	(1,344)	0	0
Acquisition of Elanco Animal Health Incorporated aqua business	(1,303)	0	0
Acquisition of Harpoon Therapeutics, Inc., net of cash acquired	(746)	0	0
Acquisition of MK-1045 from Curon Pharmaceutical	(700)	0	0
Acquisition of Prometheus Biosciences, Inc., net of cash acquired	0	(10,705)	0
Acquisition of Imago BioSciences Inc., net of cash acquired	0	(1,327)	0
Other	(127)	(36)	(89)
Net Cash Used in Investing Activities	(7,734)	(14,083)	(4,960)
Cash Flows from Financing Activities
Payments on debt	(1,290)	(1,755)	(2,251)
Proceeds from issuance of debt	3,599	5,939	0
Purchases of treasury stock	(1,306)	(1,346)	0
Dividends paid to stockholders	(7,840)	(7,445)	(7,012)
Proceeds from exercise of stock options	177	125	384
Other	(372)	(328)	(240)
Net Cash Used in Financing Activities	(7,032)	(4,810)	(9,119)
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash	(293)	23	(410)
Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash	6,409	(5,864)	4,606
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes $68, $79 and $71 of restricted cash at January 1, 2024, 2023 and 2022, respectively, included in Other current assets)	6,909	12,773	8,167
Cash, Cash Equivalents and Restricted Cash at End of Year (includes $76, $68 and $79 of restricted cash at December 31, 2024, 2023 and 2022, respectively, included in Other current assets)	$ 13,318	$ 6,909	$ 12,773